Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission – results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trialAlexander Schmitz, Karen Dybkær, Anders Waage et al.|BMC Cancer|2022Cited by 7
Minimal Residual Disease (MRD) follow up of MM patients obtaining stringent complete remission (sCR) in the NMSG/EMN02 clinical trial – defining sCR numbers and prediction of disease progression by multiparametric flow cytometry (MFC).Hans Erik Johnsen, Karen Dybkær, Alexander Schmitz et al.|VBN Forskningsportal (Aalborg Universitet)|2018Cited by 0